• English

  • Bengali

  • Hindi


Medical School

  • Medical College and Hospital, Kolkata / Calcutta Medical College , 2004 , Kolkata , India


  • SUNY Downstate College of Medicine , 2008 , Brooklyn , NY

Graduate Degree

MS, Clinical and Translational Science
  • Mayo Clinic School of Graduate Medical Education , 2011 , Rochester , MN


Pediatric Hematology/Oncology
  • Mayo Clinic , 2011 , Rochester , MN


Pediatric Thrombosis/Hemostasis
  • The Hospital for Sick Children , 2013 , Toronto, Ontario , Canada


Dr. Riten Kumar is the clinical director of the Thrombosis and Anticoagulation Program at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dr. Kumar received his medical degree from Calcutta Medical College in India. He then completed his pediatric residency at State University of New York. He finished his pediatric hematology-oncology fellowship at the Mayo Clinic in Minnesota while also earning his Master's in Clinical and Translational Science from the Mayo School of Graduate Medical Education. In 2013, he completed a second fellowship in Pediatric Thrombosis and Hemostasis at the Hospital for Sick Children, University of Toronto in Canada.


  • American Board of Pediatrics, General Pediatrics
  • American Board of Pediatrics, Pediatric Hematology and Oncology


Publications powered by Harvard Catalyst Profiles

  1. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood. 2021 04 25. View abstract
  2. Bleeding Severity and Phenotype in 22q11.2 Deletion Syndrome - A Cross-sectional Investigation. J Pediatr. 2021 Apr 06. View abstract
  3. Unfractionated heparin using actual body weight without dose capping in obese pediatric patients-Subgroup analysis from an observational cohort study. Pediatr Blood Cancer. 2021 Mar; 68(3):e28872. View abstract
  4. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv. 2020 12 22; 4(24):6250-6258. View abstract
  5. Venous thromboembolism in children with central nervous system tumors: Comparison of an institutional cohort to a national administrative database. Pediatr Blood Cancer. 2021 Mar; 68(3):e28846. View abstract
  6. Fibrinogen Columbus III: A novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer. 2021 Mar; 68(3):e28713. View abstract
  7. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020 07; 18(7):1672-1685. View abstract
  8. Catheter-directed thrombolysis for submassive pulmonary embolism in children: A case series. Pediatr Blood Cancer. 2020 04; 67(4):e28144. View abstract
  9. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan; 7(1):e18-e27. View abstract
  10. Popliteal Artery Entrapment Syndrome Presenting with Critical Limb Ischemia in an Adolescent. J Pediatr. 2020 02; 217:215-215.e1. View abstract
  11. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019 Oct; 6(10):e500-e509. View abstract
  12. Fibrinogen Columbus II: A novel c.1075G>T mutation in the FGG gene causing hypodysfibrinogenemia and thrombosis in an adolescent male. Pediatr Blood Cancer. 2019 09; 66(9):e27832. View abstract
  13. Valproic Acid-Induced Coagulopathy. Pediatr Neurol. 2019 09; 98:25-30. View abstract
  14. Anti-Factor Xa-Based Monitoring of Unfractionated Heparin: Clinical Outcomes in a Pediatric Cohort. J Pediatr. 2019 06; 209:212-219.e1. View abstract
  15. Impact of erythrocytapheresis on natural anticoagulant levels in children with sickle cell disease: A pilot study. Pediatr Blood Cancer. 2019 04; 66(4):e27588. View abstract
  16. Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation. J Pediatr. 2019 04; 207:226-232.e1. View abstract
  17. Klinefelter syndrome as a risk factor for recurrent deep vein thrombosis in an adolescent male: Significance of a thorough physical examination. Pediatr Blood Cancer. 2018 08; 65(8):e27080. View abstract
  18. Venous Thromboembolism in Children with Sickle Cell Disease: A Retrospective Cohort Study. J Pediatr. 2018 06; 197:186-190.e1. View abstract
  19. Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study. Blood Adv. 2018 02 13; 2(3):285-291. View abstract
  20. Risk Factors for Neonatal Venous and Arterial Thromboembolism in the Neonatal Intensive Care Unit-A Case Control Study. J Pediatr. 2018 04; 195:28-32. View abstract
  21. Mesoaortic compression of a left-sided inferior vena-cava presenting as recurrent pulmonary embolism in a child-a novel anatomic thrombophilia? Pediatr Blood Cancer. 2018 06; 65(6):e26986. View abstract
  22. Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: A Multicenter Cohort Study. Biol Blood Marrow Transplant. 2018 02; 24(2):337-342. View abstract
  23. Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience. J Pediatr Hematol Oncol. 2017 10; 39(7):576-577. View abstract
  24. Thrombosis of the Abdominal Veins in Childhood. Front Pediatr. 2017; 5:188. View abstract
  25. Inferior vena cava atresia predisposing to acute lower extremity deep vein thrombosis in children: A descriptive dual-center study. Pediatr Blood Cancer. 2018 Feb; 65(2). View abstract
  26. Arterial Ischemic Stroke in Children and Young Adults. Continuum (Minneap Minn). 2017 02; 23(1, Cerebrovascular Disease):158-180. View abstract
  27. Thrombocytopenia Pitfalls: Misdiagnosing Type 2B von Willebrand Disease as Ethylenediaminetetraacetic Acid-Dependent Pseudothrombocytopenia. J Pediatr. 2016 Aug; 175:238-238.e1. View abstract
  28. Molecular structural analysis of a novel and de-novo mutation in the SERPINC1 gene associated with type 1 antithrombin deficiency. Br J Haematol. 2017 05; 177(4):654-656. View abstract
  29. Impact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia. Thromb Haemost. 2016 06 02; 115(6):1120-8. View abstract
  30. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy. Semin Thromb Hemost. 2016 Feb; 42(1):18-29. View abstract
  31. aPTT in children receiving UFH: time for a change? Blood. 2015 Oct 29; 126(18):2075-6. View abstract
  32. c.1058C>T variant in the SERPINC1 gene is pathogenic for antithrombin deficiency. Br J Haematol. 2015 Jul; 170(1):123-5. View abstract
  33. Prevalence and risk factors for post thrombotic syndrome after deep vein thrombosis in children: a cohort study. Thromb Res. 2015 Feb; 135(2):347-51. View abstract
  34. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol. 2014 Dec; 37(6):635-41. View abstract
  35. Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study. Br J Haematol. 2014 Jul; 166(1):130-9. View abstract
  36. Health-related quality of life in children and young adults with post-thrombotic syndrome: results from a cross-sectional study. Pediatr Blood Cancer. 2014 Mar; 61(3):546-51. View abstract
  37. Inherited abnormalities of coagulation: hemophilia, von Willebrand disease, and beyond. Pediatr Clin North Am. 2013 Dec; 60(6):1419-41. View abstract
  38. Congenital thrombocytopenia: clinical manifestations, laboratory abnormalities, and molecular defects of a heterogeneous group of conditions. Hematol Oncol Clin North Am. 2013 Jun; 27(3):465-94. View abstract
  39. Consequences of delayed therapy for sports-related bleeds in patients with mild-to-moderate haemophilia and type 3 von Willebrand's disease not on prophylaxis. Haemophilia. 2013 Jul; 19(4):e264-7. View abstract
  40. A novel mutation in the SerpinC1 gene presenting as unprovoked neonatal cerebral sinus venous thrombosis in a kindred. Pediatr Blood Cancer. 2013 Jan; 60(1):133-6. View abstract
  41. Treatment of Hodgkin's lymphoma in a patient with type III von Willebrand's disease. Haemophilia. 2012 Sep; 18(5):e378-9. View abstract
  42. Pretransplant conditioning with Campath-1H (alemtuzumab) in pediatric matched unrelated hematopoietic stem cell transplants: an institutional experience. J Pediatr Hematol Oncol. 2012 Mar; 34(2):96-100. View abstract
  43. Development and initial validation of a questionnaire to diagnose the presence and severity of post-thrombotic syndrome in children. Pediatr Blood Cancer. 2012 Apr; 58(4):643-4. View abstract
  44. Postradiation dermatofibrosarcoma protuberans in a patient with Wilms tumor. J Pediatr Hematol Oncol. 2011 Dec; 33(8):635-6. View abstract
  45. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma. Pediatr Blood Cancer. 2011 Aug; 57(2):317-20. View abstract
  46. Pelvic pseudotumor and pseudoaneurysm in a pediatric patient with moderate hemophilia B: successful management with arterial embolization and surgical excision. Pediatr Blood Cancer. 2011 Mar; 56(3):484-7. View abstract
  47. Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A. Pediatr Blood Cancer. 2011 Feb; 56(2):307-10. View abstract
  48. Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion. Pediatr Blood Cancer. 2011 Mar; 56(3):467-9. View abstract
  49. A short course of prednisone in the management of acute chest syndrome of sickle cell disease. J Pediatr Hematol Oncol. 2010 Apr; 32(3):e91-4. View abstract
  50. A severe case of acute generalized exanthematous pustulosis (AGEP) in a child after the administration of amoxicillin-clavulanic acid: brief report. Pediatr Dermatol. 2009 Sep-Oct; 26(5):623-5. View abstract
  51. Non-catheter related internal jugular vein thrombosis in a patient with severe haemophilia A. Haemophilia. 2009 Nov; 15(6):1339-40. View abstract